These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Niederle MB; Hackl M; Kaserer K; Niederle B Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725 [TBL] [Abstract][Full Text] [Related]
3. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696 [TBL] [Abstract][Full Text] [Related]
4. Laboratory tests for neuroendocrine tumours. Seregni E; Ferrari L; Stivanello M; Dogliotti L Q J Nucl Med; 2000 Mar; 44(1):22-41. PubMed ID: 10932599 [TBL] [Abstract][Full Text] [Related]
6. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Lepage C; Rachet B; Coleman MP Gastroenterology; 2007 Mar; 132(3):899-904. PubMed ID: 17383419 [TBL] [Abstract][Full Text] [Related]
7. [Hereditary syndromes of neuroendocrine tumours]. Kaemmerer D; Posorski N; Hommann M; Baum RP; Hörsch D Zentralbl Chir; 2014 Aug; 139(4):415-27. PubMed ID: 24327486 [TBL] [Abstract][Full Text] [Related]
8. [Incidence, pathology and clinical course and symptoms of neuroendocrine gastrointestinal tumours]. Federspiel BH; Hansen CP; Vainer B; Hasselby JP; Bardram L; Knigge U Ugeskr Laeger; 2010 Oct; 172(43):2946-50. PubMed ID: 21040672 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of neuroendocrine tumours. Taal BG; Visser O Neuroendocrinology; 2004; 80 Suppl 1():3-7. PubMed ID: 15477707 [TBL] [Abstract][Full Text] [Related]
10. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156 [TBL] [Abstract][Full Text] [Related]
11. [Contemporary methods of diagnosis and treatment of neuroendocrine gastrointestinal tumors]. Kos-Kudła B; Zemczak A Endokrynol Pol; 2006; 57(2):174-86. PubMed ID: 16773594 [TBL] [Abstract][Full Text] [Related]
12. [Pathological implications in the neuroendocrine gastrointestinal system]. Piette C; Polus M; Louis E Rev Med Liege; 2002 Aug; 57(8):509-18. PubMed ID: 12405024 [TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumors in children and young adults: rare or not so rare. Sarvida ME; O'Dorisio MS Endocrinol Metab Clin North Am; 2011 Mar; 40(1):65-80, vii. PubMed ID: 21349411 [TBL] [Abstract][Full Text] [Related]
14. [Neuroendocrine tumours of pancreas and gastrointestinal tract]. Tsimmerman IaS Klin Med (Mosk); 2009; 87(12):7-13. PubMed ID: 20135878 [TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855 [TBL] [Abstract][Full Text] [Related]
17. [Multidisciplinary approach in the diagnosis and therapy of patients with endocrine tumors]. Díez JJ; Grande E; Alonso T; Iglesias P Med Clin (Barc); 2015 Jul; 145(1):36-41. PubMed ID: 25726308 [No Abstract] [Full Text] [Related]
18. The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET). Kanakis G; Kamp K; Tsiveriotis K; Feelders RA; Zormpala A; de Herder WW; Kaltsas G Clin Endocrinol (Oxf); 2013 Jun; 78(6):950-6. PubMed ID: 22970733 [TBL] [Abstract][Full Text] [Related]
19. European disparities in malignant digestive endocrine tumours survival. Lepage C; Ciccolallo L; De Angelis R; Bouvier AM; Faivre J; Gatta G; Int J Cancer; 2010 Jun; 126(12):2928-34. PubMed ID: 19569047 [TBL] [Abstract][Full Text] [Related]
20. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Modlin IM; Champaneria MC; Chan AK; Kidd M Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]